Precigen (PGEN) Stock Overview
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PGEN Community Fair Values
Create NarrativeSee what 37 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Precigen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.89 |
| 52 Week High | US$5.47 |
| 52 Week Low | US$1.11 |
| Beta | 1.16 |
| 1 Month Change | 1.30% |
| 3 Month Change | -6.49% |
| 1 Year Change | 144.65% |
| 3 Year Change | 266.98% |
| 5 Year Change | -44.35% |
| Change since IPO | -84.27% |
Recent News & Updates
Recent updates
Precigen: The Best Potential Blockbuster You've Never Heard Of (Your ENT Has)
Mar 26Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement
Feb 28Precigen: Successful Proof Of Platform, But Cash Worries Remain
Feb 10We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate
Feb 28
Precigen: RRP Targeting With AdenoVerse Technology Platform
Jan 20Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?
Nov 04Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?
Jul 18Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade
May 15Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio
Apr 18Shareholder Returns
| PGEN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 18.6% | 0.9% | -0.1% |
| 1Y | 144.7% | 25.0% | 15.9% |
Return vs Industry: PGEN exceeded the US Biotechs industry which returned 25% over the past year.
Return vs Market: PGEN exceeded the US Market which returned 15.9% over the past year.
Price Volatility
| PGEN volatility | |
|---|---|
| PGEN Average Weekly Movement | 12.7% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: PGEN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PGEN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 143 | Helen Sabzevari | precigen.com |
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors.
Precigen, Inc. Fundamentals Summary
| PGEN fundamental statistics | |
|---|---|
| Market cap | US$1.38b |
| Earnings (TTM) | -US$429.64m |
| Revenue (TTM) | US$9.68m |
Is PGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PGEN income statement (TTM) | |
|---|---|
| Revenue | US$9.68m |
| Cost of Revenue | US$4.82m |
| Gross Profit | US$4.86m |
| Other Expenses | US$434.50m |
| Earnings | -US$429.64m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.21 |
| Gross Margin | 50.20% |
| Net Profit Margin | -4,436.62% |
| Debt/Equity Ratio | 445.6% |
How did PGEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/27 01:26 |
| End of Day Share Price | 2026/03/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Precigen, Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ying Huang | Barclays |
| Derik de Bruin | BofA Global Research |
| Justin Walsh | B. Riley Securities, Inc. |